Antinuclear Antibody Spectrum Test Kit(ANAs) 24 tests/kit
Excellent specificity and sensitivity (> 95%);
Rapid procedures (< 30 minutes);
Simultaneous screening of 7 diseases;
Superior batch-to-batch reproducibility.
Rapid procedures (< 30 minutes);
Simultaneous screening of 7 diseases;
Superior batch-to-batch reproducibility.
Comprehensive Diagnostic Markers
Differential Diagnosis
Rapid, Accurate and Easy Interpretation, ANA
Product parameters
Assay Principle Immunoblotting |
Sample Type Serum |
|
Positive Coincidence Rate The positive coincidence rate of each item is the same |
Negative Coincidence Rate The negative coincidence rate of each item is the same |
|
Intra Batch Repeatability Repeat 10 tests, and the test results are consistent |
Inter Batch Repeatability Repeat 10 tests, and the test results are consistent |
Assay Principle Immunoblotting |
Positive Coincidence Rate The positive coincidence rate of each item is the same |
Intra Batch Repeatability Repeat 10 tests, and the test results are consistent |
Sample Type Serum |
Negative Coincidence Rate The negative coincidence rate of each item is the same |
Inter Batch Repeatability Repeat 10 tests, and the test results are consistent |
Clinical significance
Introduction
Antinuclear antibodies (ANA) are a group of autoantibodies that specifically target substances in the nucleus of cells. One group of ANAs represent autoantibodies against extractable nuclear antigens, such as SS-A/Ro, SS-B/La, Sm, RNP, Scl-70 and Jo-1, which are mainly ribonucleoproteins and nuclear enzymes. Another group of ANAs are against nucleic acids (dsDNA), complexes of nuclear proteins and histones.
Detection and classification of these ANAs in human blood are important for differential diagnosis of systemic autoimmune diseases (SAD). Utilization of high-quality autoantigens for the screening and semi-quantification of specific ANAs has been routinely used in clinical practice for precision diagnosis and monitoring the progression of these diseases.
Clinical Significance
Simultaenous detection of 7 major autoimmune diseases including systemic lupus erythematosus (SLE), Sjogren's syndrome (SS), Mixed Connective Tissue Disease, CREST Syndrome, Systemic Sclerosis, Polymyositis and Dermatomyositis.
Intended Use
It is used for qualitative detection of IgG antibodies in human serum, such as Jo-1, Mi-2, Ku, snrnp-a, snrnp-c, snrnp-68 / 70, SMB / B, dsDNA, histones, PCNA, P0, SSA / Ro-52, SSA / ro-60, SSB / LA, M2, CenpB, ScL-70 and pmscl.
Antinuclear antibodies (ANA) are a group of autoantibodies that specifically target substances in the nucleus of cells. One group of ANAs represent autoantibodies against extractable nuclear antigens, such as SS-A/Ro, SS-B/La, Sm, RNP, Scl-70 and Jo-1, which are mainly ribonucleoproteins and nuclear enzymes. Another group of ANAs are against nucleic acids (dsDNA), complexes of nuclear proteins and histones.
Detection and classification of these ANAs in human blood are important for differential diagnosis of systemic autoimmune diseases (SAD). Utilization of high-quality autoantigens for the screening and semi-quantification of specific ANAs has been routinely used in clinical practice for precision diagnosis and monitoring the progression of these diseases.
Clinical Significance
Simultaenous detection of 7 major autoimmune diseases including systemic lupus erythematosus (SLE), Sjogren's syndrome (SS), Mixed Connective Tissue Disease, CREST Syndrome, Systemic Sclerosis, Polymyositis and Dermatomyositis.
Intended Use
It is used for qualitative detection of IgG antibodies in human serum, such as Jo-1, Mi-2, Ku, snrnp-a, snrnp-c, snrnp-68 / 70, SMB / B, dsDNA, histones, PCNA, P0, SSA / Ro-52, SSA / ro-60, SSB / LA, M2, CenpB, ScL-70 and pmscl.